Patents by Inventor Gerald McMahon

Gerald McMahon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
    Patent number: 6114371
    Abstract: The present invention relates to novel 3-(cyclohexano-heteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: September 5, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Robert A. Blake
  • Quinazolines
    Patent number: 6103728
    Abstract: Molecules that are capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities. These compounds have the structural formula ##STR1## wherein R1-R10 are disclosed in the specification. The specification also provides pharmaceutical compositions and methods for inhibiting cell proliferation or differentiation and related disorders.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: August 15, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Gerald McMahon
  • Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds
    Patent number: 6093728
    Abstract: The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with azabenzimidazole-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to azabenzimidazole compounds and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: September 23, 1998
    Date of Patent: July 25, 2000
    Assignee: Asta Medica Aktiengesellschaft
    Inventors: Gerald McMahon, Heinz Weinberger, Bernhard Kutscher, Harald App
  • Methods and compositions for inhibition of adaptor protein/tyrosine kinase interactions
    Patent number: 6090838
    Abstract: The present invention relates to methods and compositions for the inhibition of adaptor protein/protein tyrosine kinase protein interactions, especially wherein those interactions involving a protein tyrosine kinase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins are associated with a cell proliferative disorder. Specifically, the present invention relates to particular compounds, especially quinazoline derivative compounds, and methods utilizing such compounds.
    Type: Grant
    Filed: June 4, 1998
    Date of Patent: July 18, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Gerald McMahon, G. Davis Harris
  • 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
    Patent number: 6051593
    Abstract: The present invention relates to novel 3-(cycloalkanoheteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: April 18, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Psoriasis treatment with quinazoline compounds
    Patent number: 6004967
    Abstract: This invention is directed to methods and compositions for treating hyperproliferative skin disorders utilizing a quinazoline derivative as an active ingredient.
    Type: Grant
    Filed: September 11, 1997
    Date of Patent: December 21, 1999
    Assignee: Sugen, Inc.
    Inventors: Gerald McMahon, Laura Shawver, Blair Narog, Peng Cho Tang, Klaus Peter Hirth
  • Tyrphostin like compounds
    Patent number: 5935993
    Abstract: The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: August 10, 1999
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Asaad S. Nematalla, Gerald McMahon
  • Certain acrylonitrile-sulfonamide derivatives
    Patent number: 5891917
    Abstract: The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: April 6, 1999
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Asaad S. Nematalla, Gerald McMahon
  • Thienyl compounds for inhibition of cell proliferative disorders
    Patent number: 5886195
    Abstract: The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities.
    Type: Grant
    Filed: November 17, 1997
    Date of Patent: March 23, 1999
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Asaad S. Nematalla, Gerald McMahon
  • 3-(4'-dimethylaminobenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease
    Patent number: 5886020
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: June 5, 1996
    Date of Patent: March 23, 1999
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Pharmaceutical compositions and methods for modulating signal transduction
    Patent number: 5883110
    Abstract: The present invention relates to organic molecules capable of inhibiting protein tyrosine phosphatase activity. The invention further relates to the use of such molecules to modulate or regulate signal transduction by inhibiting protein tyrosine phosphatase activity. Finally, the invention relates to the use of such molecules to treat various disease states including diabetes mellitus.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: March 16, 1999
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Gerald McMahon
  • 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
    Patent number: 5883113
    Abstract: The present invention relates to organic molecules apable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal ell proliferation.
    Type: Grant
    Filed: June 5, 1996
    Date of Patent: March 16, 1999
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • 3-(2'-alkoxybenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease
    Patent number: 5883116
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: June 5, 1996
    Date of Patent: March 16, 1999
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Benzylidene-Z-indoline compounds for the treatment of disease
    Patent number: 5880141
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 9, 1999
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • 3-(2'-halobenzylidenyl)-2-indolinone compounds for the treatment of disease
    Patent number: 5834504
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: June 5, 1996
    Date of Patent: November 10, 1998
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Methods of inhibiting phosphatase activity and treatment of disorders associated therewith
    Patent number: 5798374
    Abstract: The present invention relates to organic molecules capable of inhibiting protein tyrosine phosphatase activity. The invention further relates to the use of such molecules to modulate or regulate signal transduction by inhibiting protein tyrosine phosphatase activity. Finally, the invention relates to the use of such molecules to treat various disease states including diabetes mellitus.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 25, 1998
    Assignee: Sugen Inc.
    Inventors: Peng Cho Tang, Gerald McMahon
  • 3-heteroaryl-2-indolinone compounds for the treatment of disease
    Patent number: 5792783
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: June 5, 1996
    Date of Patent: August 11, 1998
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions
    Patent number: 5780496
    Abstract: The present invention relates to methods and compositions for the inhibition of adaptor protein/protein tyrosine kinase protein interactions, especially wherein those interactions involving a protein tyrosine kinase capable of completing with a member of the SH2- and/or SH3-containing family of adaptor proteins are associated with a cell proliferative disorder. Specifically, the present invention relates to particular compounds, especially quinazoline derivative compounds, and methods utilizing such compounds.
    Type: Grant
    Filed: June 5, 1996
    Date of Patent: July 14, 1998
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Gerald McMahon, G. Davis Harris
  • Urea- and thiourea-type compounds
    Patent number: 5773459
    Abstract: The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 30, 1998
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Gerald McMahon
  • Benzopyran compounds and methods for their use
    Patent number: 5763470
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 9, 1998
    Assignee: Sugen Inc.
    Inventors: Peng Cho Tang, Gerald McMahon